The landscape of isoform switches in human cancers

Molecular Cancer Research

Volumn 15, Issue 9, 2017, Pages 1206-1220

  Vitting Seerup, Kristoffer ^a   Sandelin, Albin ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; RNA ISOFORM; ISOPROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLON ADENOCARCINOMA; CONTROLLED STUDY; DNA BASE COMPOSITION; DNA SEQUENCE; EXON; GENE EXPRESSION; GENE LIBRARY; GENE SWITCHING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON RETENTION; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASM; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PAPILLARY CARCINOMA; PLECKSTRIN HOMOLOGY DOMAIN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DOMAIN; PROTEIN INTERACTION; RENAL CELL CARCINOMA; RNA SEQUENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL RATE; THYROID CARCINOMA; GENE EXPRESSION PROFILING; GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE; PROCEDURES;

BASE SEQUENCE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; PROTEIN ISOFORMS;

EID: 85028799493     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0459     Document Type: Article

References (49)

1. Barbosa-Morais NL, Irimia M, PanQ, Xiong HY, Gueroussov S, Lee LJ, et al. The evolutionary landscape of alternative splicing in vertebrate species. Science 2012;338:1587-93.
2. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008;40:1413-5.
3. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 2006;38:626-35.
4. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74.
5. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Muñoz MJ. Alternative splicing: A pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 2013;14:153-65.
6. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative premRNA splicing. Mol Cell 2005;19:1-13.
7. Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
8. Kalsotra A, Cooper TA. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet 2011;12:715-29.
9. Ye J, Blelloch R. Regulation of pluripotency by RNA binding proteins. Cell Stem Cell 2014;15:271-80.
10. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470-6.
11. Davuluri R V., Suzuki Y, Sugano S, Plass C, Huang TH. The functional consequences of alternative promoter use inmammalian genomes. Trends Genet 2008;24:167-77.
12. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009;6: 454-60.
13. Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 2015;526:453-7.
14. Sveen A, Kilpinen S, Ruusulehto A, Lothe Ra, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2015;1-15.
15. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
16. Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med 2016;22:976-86.
17. Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012;11:847-59.
18. Trapnell C, Williams BB A, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010;28:511-5.
19. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016;34:525-7.
20. Bao J, Vitting-Seerup K, Waage J, Tang C, Ge Y, Porse BT, et al. UPF2-dependent nonsense-mediated mRNA decay pathway is essential for spermatogenesis by selectively eliminating longer 30UTR transcripts. PLOS Genet 2016;12:e1005863.
21. Mel-eM, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth M, et al. The human transcriptome across tissues and individuals. Science 2015; 348:660-5.
22. Forrest AR, Kawaji H, Rehli M, Baillie JK, de HoonMJ, Lassmann T, et al. A promoter-level mammalian expression atlas. Nature 2014;507:462-70.
23. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNAseq. Nat Biotechnol 2013;31:46-53.
24. Niu L, Huang W, Umbach DM, Li L. IUTA: A tool for effectively detecting differential isoform usage from RNA-Seq data. BMC Genomics 2014;15: 862.
25. Shi Y, Chinnaiyan AM, Jiang H. rSeqNP: A non-parametric approach for detecting differential expression and splicing from RNA-Seq data. Bioinformatics 2015;31:2222-4.
26. Nowicka M, Robinson MD. DRIMSeq: A Dirichlet-multinomial framework for multivariate count outcomes in genomics. F1000Res 2016;5:1356.
27. Sebestyen E, Zawisza M, Eyras E. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res 2015;43:1345-56.
28. Zhao W, Hoadley KA, Parker JS, Perou CM. Identification ofmRNAisoform switching in breast cancer. BMC Genomics 2016;17:181.
29. Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, et al. Integrated exome and transcriptome sequencing reveals ZAK isoformusage in gastric cancer. Nat Commun 2014;5:1-8.
30. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, et al. The Pfam protein families database. Nucleic Acids Res 2012;40:D290-301.
31. Emanuelsson O, Brunak S, von Heijne G, Nielsen H. Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc 2007; 2:953-71.
32. Vitting-Seerup K, Porse BT, Sandelin A, Waage J. spliceR: An R package for classification of alternative splicing and prediction of coding potential from RNA-seq data. BMC Bioinformatics 2014;15:81.
33. Li B, Dewey CN. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011;12: 323.
34. Weischenfeldt J, Waage J, Tian G, Zhao J, Damgaard I, Jakobsen JS, et al. Mammalian tissues defective in nonsense-mediated mRNA decay display highly aberrant splicing patterns. Genome Biol 2012;13:R35.
35. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: Discriminating signal peptides from transmembrane regions. Nat Methods 2011;8:785-6.
36. Wang L, Park HJ, Dasari S, Wang S, Kocher J-P, Li W. CPAT: Coding-Potential Assessment Tool using an alignment-free logistic regression model. Nucleic Acids Res 2013;41:e74.
37. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res 2017;45:D777-83.
38. Liberzon A, Subramanian A, Pinchback R, Thorvaldsd-ottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011;27:1739-40.
39. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-52.
40. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York, NY: Springer; 2000.
41. Oka Y, Varmark H, Vitting-Seerup K, Beli P, Waage J, Hakobyan A, et al. UBL5 is essential for pre-mRNA splicing and sister chromatid cohesion in human cells. EMBO Rep 2014;15:956-64.
42. Chin YR, Toker A. Akt isoform-specific signaling in breast cancer: Uncovering an anti-migratory role for palladin. Cell Adh Migr 2011;5:211-4.
43. Shen S, Wang Y, Wang C, Wu YN, Xing Y. SURVIV for survival analysis of mRNA isoform variation. Nat Commun 2016;7:11548.
44. Zhao Y, Zhou L, Liu B, Deng Y, Wang Y, Wang Y, et al. ZNF325, a novel human zinc finger protein with a RBaK-like RB-binding domain, inhibits AP-1- and SRE-mediated transcriptional activity. Biochem Biophys Res Commun 2006;346:1191-9.
45. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 2010;67:101-7.
46. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 2015;21:81-94.
47. Rajendran M, Thomes P, Zhang L, Veeramani S, Lin M. p66Shc - a longevity redox protein in human prostate cancer progression and metastasis : P66Shc in cancer progression and metastasis. Cancer Metastasis Rev 2010;29:207-22.
48. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88.
49. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: Transcript-level estimates improve gene-level inferences. F1000Res 2015; 4:1521.